{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-057828","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2026-05-15T20:29:39+00:00","discovered_at":"2026-05-15T20:33:00.263433+00:00","generated_at":"2026-05-15T20:34:43.159288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M","bullets":["Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.","Net loss of $3.3M ($0.05 EPS) vs $2.3M ($0.04 EPS) YoY, driven by higher other expense.","Loss from operations improved 16% to $0.8M from $1.0M, reflecting cost-cutting measures.","MENA segment sales surged 446%, partially offsetting U.S. decline.","Cash and equivalents $1.1M at March 31, 2026, down from $2.1M at December 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-057828","json":"https://secwatch.observer/filing/0001213900-26-057828.json","markdown":"https://secwatch.observer/filing/0001213900-26-057828.md","text":"https://secwatch.observer/filing/0001213900-26-057828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/0001213900-26-057828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/ea0290896-8k_emmauslife.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:34:43.159288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"710a466afa92eb5a68908addc93b378fabbbdd20","claim":"Emmaus Life Sciences, Inc. reported three months ended March 31, 2026 results: revenue $2.0 million, net income $3.3 million, EPS $0.05 basic net loss per share.","evidence_excerpt":"Net revenues for the three months ended March 31, 2026 were $2.0 million, compared to $2.4 million in the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/0001213900-26-057828-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2026"},{"label":"Revenue","value":"$2.0 million"},{"label":"Net income","value":"$3.3 million"},{"label":"EPS","value":"$0.05 basic net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}